JAPFA Legal Advisor · Deep Review · Egypt Elfath
SIGNED · 2024 RE-ENGAGEMENT
56 /100 F
Score · Grade F · Yellow-Red
Significant rework · Worst-drafted contract in JAPFA portfolio

This is a re-engagement of a counterparty Vaksindo had just terminated for missed targets — with three uniquely bad drafting defects on top.

Article 33 has dual governing law ("Indonesia OR Singapore") AND dual forum ("BANI OR SIAC") — unenforceable as drafted, will paralyse any dispute for 12-24 months. Articles 4.2 and 4.3 directly contradict each other on who owns the Egypt EDA marketing authorization. And there's no Egyptian Law 120/1982 carve-out, exposing JAPFA to potential multi-million-USD agency compensation under Articles 13-Bis-2/3.

⚠️ NOT an active termination — but draft a 30-day side-letter to fix the 5 critical defects before they're invoked
5
Critical Risks
12
Material Risks
8
Drafting Defects
2022
Prior Termination Year

Counterparty

Legal entity
Elfath
Country
Egypt (Cairo)
Relationship history
2013 — original contract; 2017 — annex; 22 January 2022 — terminated for cause (missed sales targets); 2024 — re-engagement
Current contract date
2024

Agreement

Type
Distributorship Agreement
Term
through 1 January 2029
Article numbering
Article 33 (governing law) — offset from Standard Vaksindo Art. 34
Schedule A
13 products + recent LoA refreshes (04.02.2026, 19.02.2026)
Currency
USD
🔍 Termination history — verified NOT an active termination important context

The 2022 termination + 2024 re-engagement story

The "Termination of Agreement & Annexes (1).pdf" sitting in the Elfath folder turned out to be the prior-relationship termination — not an active termination of the current agreement.

21 Jan 2013
Original contract executedVaksindo appoints Elfath as Egyptian distributor.
26 Nov 2017
Annex executedProduct list / commercial terms updated.
6 Dec 2021
Termination letter executed by VaksindoCause: missed sales targets. Egyptian Embassy legalized the termination on 30 Jan 2022.
21 Jan 2022
Termination effective dateThe 2013 contract + 2017 annex came to an end.
2024
Fresh-start re-engagementThe current Distribution Agreement reviewed here. Vaksindo re-engaged a counterparty it had just terminated for cause.
04 / 19 Feb 2026
Routine LoA refreshesProduct list updates: 19 Feb 2026 LoA drops stand-alone VAKSIMUNE IBD MHV; keeps IBH DUO. Routine, not adversarial.

Why this matters: A re-engagement of a counterparty just terminated for missed-targets cause materially raises the risk of repeat underperformance. The current contract should reflect that history — but doesn't (no enhanced minimums consequences ladder, no early-warning trip-wires, no return-to-non-exclusive option). Recommend tightening Article 7-style minimums in the side-letter.

Top 5 critical risks side-letter remediation
C1 Article 33 — DUAL governing law AND DUAL forum (unenforceable)
Art. 33.1: "the laws of Republic of Indonesia or Singapore, without regard to any laws relating to conflict of laws"
Art. 33.2: "the Parties agree to bring the dispute to BANI (Badan Arbitrase Nasional Indonesia) or in accordance with the arbitration rules of the Singapore International Arbitration Centre (SIAC Rules)"

This is the only contract in JAPFA's portfolio with both governing law AND forum disjunctive. Will paralyse any dispute for 12-24 months while the parties argue which law applies and which institution administers. Note the Article 33 numbering offset — "Art. 34" in this contract is "Waiver", not governing law.

Side-letter fix (HIGH negotiability): Pick Indonesian law + SIAC Singapore + 3 arbitrators + English language + CISG expressly excluded + KUHPerdata 1266/1267 waiver. Counterparty cannot reasonably resist a drafting cleanup that benefits both sides.
C2 Article 4.2 vs 4.3 — DIRECTLY contradicts itself on Egypt EDA Marketing Authorization ownership

Article 4.2 places the Egypt EDA Marketing Authorization with JAPFA. Article 4.3 places it with Elfath. The two clauses cannot both be true. Combined with the EDA's actual registration practice (JAPFA's vs Elfath's name) — which the agent flagged as a verification gap — this contradiction means JAPFA may not even know who legally controls market access right now.

Side-letter fix (MEDIUM): Resolve in favour of JAPFA ownership with Elfath as bailee/holder during the term; verify EDA registration files for all 13 Schedule A products + LoA-listed extras; if EDA shows Elfath, transfer to JAPFA before any termination scenario.
C3 No KUHPerdata 1266/1267 waiver + no Egypt Law 120/1982 agency-law carve-out

Two separate legal exposures:

(i) Without KUHPerdata 1266/1267 waiver, JAPFA needs Indonesian court order to terminate even on default — defeating any contractual termination right.

(ii) Without an Egypt Law 120/1982 (as amended by Law 21/2022) carve-out declaring Elfath a distributor not an agent, JAPFA is exposed to multi-million-USD Egyptian agency compensation under Articles 13-Bis-2/3 of the 1982 Law.

Side-letter fix (MEDIUM — Elfath will resist the Law 120 carve-out because it has real value to them): New Article 30.1 declaring Elfath is a distributor not an agent + waiving Law 120/1982 claims + confirming no GAFI registration as commercial agent. Plus standard 1266/1267 waiver. Pair this with the Article 33 fix as a single side-letter — Elfath wants the 33 fix too, so they'll pay for it with the 30.1.
C4 Conflict with parallel Egypt 5stars contract — overlapping products may breach Article 6 in one or both

JAPFA has another signed Egypt distribution agreement — Egypt 5stars (signed 18 Nov 2024) — also covering veterinary products. The Article 6 (Competing Products) covenant in the Elfath contract may conflict with the territory grant or product scope in the 5stars contract, or vice versa. Products listed in both Schedule A's create exclusivity collision risk.

Operational fix: Reconcile the two Schedule A's at the SKU level. Document a "Sphere of Influence" letter splitting Egyptian channels (e.g., Elfath = government tender / institutional; 5stars = private veterinary clinics) so there's no exclusivity collision. Preferable to do this BEFORE the next 31 October 2026 sales-volume confirmation cycle for either contract.
C5 Article 4.5 / 23.4 — USD 49,118 reimbursement carve-outs need clarification

The agent flagged a USD 49,118 figure tied to Articles 4.5 and 23.4 — likely registration cost reimbursement or termination-related inventory buy-back. Without clearer specification, this is a defined obligation that could be invoked unpredictably on either side.

Side-letter fix: Specify the trigger conditions, payment mechanics, currency, and date for the USD 49,118 figure. Resolve whether it's a one-way Vaksindo reimbursement or a netted obligation.
30-day action plan side-letter as foot-in-the-door

Recommended single side-letter — addresses all 5 Critical risks

Foot-in-the-door framing

Article 33 is unenforceable as drafted — neither party can rely on it in a dispute. Elfath has the same problem JAPFA has. Open the conversation as: "After our internal legal review, we noticed Article 33 won't work for either of us if we ever needed it. Here's a clean replacement plus a few related cleanups." That gets the side-letter on the table without it sounding adversarial.

Operational items parallel to the side-letter

Portfolio insight

This is the worst-drafted contract reviewed in JAPFA's portfolio so far:

BUT the side-letter is feasible because Elfath benefits from clarity too — neither party can enforce Article 33 as drafted. Start with Article 33 as the foot-in-the-door, then layer in the harder asks (Egyptian agency-law waiver, MA reconciliation).